Objective-Phospholipase A 2 , group 7 (Pla2g7) is an important mediator in cardiovascular development and diseases because of its divergent physiological and pathological functions in inflammation and oxidative stress. However, little is known about the functional role of Pla2g7 in smooth muscle cell (SMC) differentiation from stem cells. Methods and Results-In the present study, embryonic stem cells were cultivated on collagen IV-coated plates to allow SMC differentiation. Pla2g7 gene expression and activity were upregulated significantly following 4 to 14 days of cell differentiation and colocalized with SMC differentiation markers in the differentiated SMCs. Knockdown of Pla2g7 resulted in downregulation of smooth muscle-specific markers in vitro and impairment of SMC differentiation in vivo, whereas enforced expression of Pla2g7 enhanced SMC differentiation and increased reactive oxygen species generation. Importantly, enforced expression of Pla2g7 significantly increased the binding of serum response factor to SMC differentiation gene promoters, resulting in SMC differentiation, which was abolished by free radical scavenger and flavoprotein inhibitor of NADPH oxidase but not hydrogen peroxide inhibitor. Moreover, we demonstrated that nuclear factor erythroid 2-related factor 3 (Nrf3) regulates Pla2g7 gene expression through direct binding to the promoter regions of Pla2g7 gene. Conclusion-Our findings demonstrated that Pla2g7 plays a crucial physiological role in SMC differentiation from stem cells, and the fine interactions between Nrf3 and Pla2g7 are essential for SMC differentiation. (Arterioscler Thromb Vasc Biol. 2012;32:730-744.) (L. Zhang).
B y activation of specific gene program and signal pathways, embryonic stem (ES) cells can differentiate into vascular smooth muscle cells (SMCs) [1] [2] [3] [4] [5] [6] [7] and endothelial cells 8 -9 ; this differentiation is essential for vascular tissue engineering. Moreover, growing evidence suggests that stem/ progenitor cells can differentiate into vascular endothelial cells to repair damaged vascular tissues 8 -9 and SMCs to participate in neointimal formation and development 10 -12 in vivo. Therefore, it is important to understand the molecular pathways and specific gene program governing the distinct differentiation of stem cell toward vascular SMCs that could provide important insights into molecular mechanisms of SMC differentiation and novel therapeutic targets for prevention or intervention of cardiovascular diseases. To identify such signaling pathways involved in SMC differentiation, we have successfully established an efficient in vitro model for ES cell differentiation into SMCs. 5 Importantly, by using this model, we demonstrated that reactive oxygen species (ROS) generation and balance are essential for SMC differentiation from stem cells and successfully identified NADPH oxidase 4 (Nox4) 3 and the transcription factor nuclear factor erythroid 2-related factor 3 (Nrf3) 2 as 2 important regulators of ROS balance and SMC differentiation. However, the detailed molecular mechanisms of SMC differentiation from stem cells have not been fully clarified.
The plasma isoform of a platelet-activating factor (PAF) acetylhydrolase, also known as lipoprotein associated phospholipase A 2 , encoded by the phospholipase A 2 , group 7 (Pla2g7) gene in humans, is an enzyme that catalyze hydrolysis of the sn-2 ester bond of PAF and related proinflammatory phospholipids. To maintain consistency, we refer both PAF acetylhydrolase and Lp-Pla2 as Pla2g7 in this text. A substantial body of peer-reviewed population studies have suggested Pla2g7 as a cardiovascular risk marker independent of and additive to traditional risk factors. [13] [14] [15] [16] [17] [18] However, the biological role of Pla2g7 is controversial because both antiand proatherogenic functions of this enzyme have been proposed from experimental evidence. 19 Selective inhibition of Pla2g7 with darapladib significantly reduced development of advanced coronary atherosclerosis in diabetic and hypercholesterolemic swine, 20 whereas in vivo gene transfer of Pla2g7 dramatically inhibited injury-induced vessel neointimal formation and spontaneous atherosclerosis development in apolipoprotein E-deficient mice. 21 Moreover, the antiatherogenic properties of Pla2g7 are attributed to the inactivity of PAF and PAF-like oxidized phospholipids, 22 2 wellknown biologically active mediators of inflammatory processes. The proinflammatory/proatherogenic role of Pla2g7 is supported by the observation that during the hydrolysis of oxidized phospholipids, this enzyme generates lysophosphatidylcholine and oxidized free fatty acids, both of which exhibit several proatherogenic effects such as oxidative stress. 23 Furthermore, PLA2G7-deficient mice (24 hours before or after their death) have recently been found to be protected from early death but to be made more susceptible to necrotizing enterocolitis development, in response to bacterial exposure, formula feeding, and asphyxia, by increasing proinflammatory gene expression in PLA2G7-knockout animals. 24 Taken together, this evidence strongly suggests that Pla2g7 is an important regulator in inflammatory processes, oxidative stress, or ROS balance, functioning as a potent antioxidative or prooxidative signal molecule by inactivating or generating oxidative products, respectively. However, there is no report showing the functional involvement of Pla2g7 in SMC differentiation from stem/progenitor cells and cardiovascular system development. In the present study, we demonstrated for the first time that Pla2g7 gene expression is essential for SMC differentiation, which is closely regulated by Nrf3, and that fine tuning the regulation of the Nrf3-Pla2g7 interaction is crucial for SMC differentiation from stem cells.
Materials and Methods

ES Cell Culture and SMC Differentiation
Detailed protocols for mouse ES cell (ES-D3 cell line CRL-1934, American Type Culture Collection, Manassas, VA) culture and SMC differentiation were as described in our previous studies. [1] [2] [3] [4] [5] [6] [7] Briefly, for SMC differentiation, undifferentiated ES cells were seeded on mouse collagen IV (5 g/mL)coated flasks or plates in differentiation medium (MEM-␣ medium [Gibco] supplemented with 10% fetal bovine serum, 0.1 mmol/L 2-mercaptoethanol, 100 U/mL penicillin, and 100 g/mL streptomycin) for 4 to 14 days before further treatment. The medium was refreshed every other day. For H 2 O 2 treatment, the predifferentiated ES cells (day 6) were cultured in serum-free H 2 O 2 basal medium (MEM-␣ medium supplemented with 1% bovine serum albumin, 10 ng/mL insulin, 100 U/mL penicillin, and 100 g/mL streptomycin) for 1 hour, followed by the addition of different amounts of H 2 O 2 (Sigma-Aldrich) and further incubation for 5 hours. For inhibitors treatment, differentiating ES cells were treated with the free radical scavenger N-(2-mercaptopropionyl)-glycine (Sigma-Aldrich, 200 mol/L), flavoprotein inhibitor of NADPH oxidase-diphenylene iodonium (DPI) (2 nmol/L, Sigma-Aldrich), or hydrogen peroxide inhibitor (catalase, 3000 U/mL, Sigma-Aldrich) 14 to 16 hours before harvest for gene/protein expression analysis or chromatin immunoprecipitation (ChIP) assay. In some specific experiments, cells were treated with actinomycin D in dimethyl sulfoxide (1 g/mL) for 6 hours before harvesting for gene expression analysis.
Cloning of Pla2g7 Gene Expression and Reporter Plasmids
Mouse full-length Pla2g7 gene was amplified by reverse transcription-polymerase chain reaction (RT-PCR) from 8 days of differentiating ES cells with the primer set shown in Table I in the online-only Data Supplement and cloned into the SalI/XbaI sites of the pCMV5 expression vector, designated pCMV5-Pla2g7. Four DNA fragments, each representing 1 region of mouse Pla2g7 gene promoter DNA sequence, were amplified by PCR from mouse genomic DNA with primer set as shown in Table I in the online-only Data Supplement and cloned into the NheI/HindIII sites of the pGL3-enhancer expression vector (Promega), designated pGL3-mPla2g7-P1, -P2, -P9, and -P10, respectively. Nrf3 expression plasmids and its specific control vectors used in this study are described in detail in our previous studies. 2 All the vectors were verified by DNA sequencing.
Pla2g7 Knockdown and In Vivo SMC Differentiation
Lentiviral particles were produced using MISSION short hairpin RNA (shRNA) Pla2g7 plasmids DNA (NM_013737, Sigma-Aldrich) according to protocol provided. The shRNA nontargeting control vector (SHC002) was used as a negative control. Briefly, 293T cells were transfected with the lentiviral vector and the packaging plasmids pCMV-dR8.2 and pCMV-VSV-G (both obtained from Addgene) using FuGene 6. The supernatant containing the lentivirus was harvested 48 hours later, filtered, aliquoted, and stored at Ϫ80°C. p24 antigen ELISA (Zeptometrix) was used to determine the viral titer. The transducing unit was calculated using the conversion factor recommended by the manufacturer (10 4 physical particles per pg of p24 and 1 transducing unit per 10 3 physical particles for a VSV-G pseudotyped lentiviral vector), with 1 pg of p24 antigen converted to 10 transducing units. For lentiviral infection, ES cells were plated 24 hours before infection in 6-well plates at 37°C. One transducing unit per cell (or 2-3ϫ10 6 /well) of shRNA or control virus were added with 10 g/mL hexadimethrine bromide (H9268, Sigma-Aldrich). Viral constructs were incubated for 24 hours with the cells before the medium was replaced with complete medium containing 2 g/mL puromycin (P9620, Sigma-Aldrich). For selection of transductants, fresh medium containing puromycin was added at 2-to 3-day intervals for 10 days. Stably infected cells were split and frozen for future experiments. For in vivo SMC differentiation, nontarget and Pla2g7 shRNA-infected ES cells were infected with adenovirus encoding LacZ gene (multiplicity of infection, 20) overnight. Cells (10 6 in 50 L) were mixed with 50 L of Matrigel (Becton Dickinson Labware) and platelet-derived growth factor-BB (100 ng/mL) at 4°C and subcutaneously injected into C57BL/6J mice. After 13 days, mice were euthanized, and the implants (Matrigel plugs) were harvested, frozen in liquid nitrogen, and prepared for hematoxylin/eosin staining or used for detection of cell markers by immunofluorescent staining and real-time PCR analysis. All animal experiments were performed according to protocols approved by the King's College London Institutional Committee for Use and Care of Laboratory Animals.
ChIP
The ChIP assays were performed as described previously. 1-2 Differentiating ES cells transfected with pCMV5-Pla2g7/pef-BOS-Nrf3 or pCMV5/pef-BOS were treated with 1% (vol/vol) formaldehyde at room temperature for 10 minutes and then quenched with glycine at room temperature. The medium was removed, and cells were harvested for sonication. The sheared samples were diluted into 1 mL of immunoprecipitation buffer containing 25 mmol/L Tris-HCl, pH 7.2, 0.1% NP-40, 150 mmol/L NaCl, and 1 mmol/L EDTA, and immunoprecipitation was conducted with antibodies raised against Nrf3 and serum response factor (SRF), together with single-strand salmon sperm DNA saturated with protein G-Sepharose beads.
Normal IgG was used as a control. The immunoprecipitates were eluted from the beads using 100 L of elution buffer (50 mmol/L NaHCO3, 1% SDS). A total of 200 L of proteinase K solution was added, for a total elution volume of 300 L, and incubated at 60°C overnight. Immunoprecipitated DNA was extracted, purified, and then used to amplify target sequences by PCR. The primers used to amplify the promoter regions of Pla2g7 gene, smooth muscle (SM)␣A, and SM22␣ were shown in Table I . For each genomic region or antibody, the immunoprecipitation efficiency was determined by calculating the percentage of the amount of DNA in immunoprecipitation samples and input samples. Fold of relative binding (fold enrichment) of each genomic region was defined as the ratio of band intensity semiquantified with ImageJ software in ChIP samples to that in the input sample, with that of pCMV5 treated with vehicle group set as 1.0.
Pla2g7 Activity Assay
The activity of Pla2g7 (extracellular PAF acetylhydrolase) was assayed with the PAF acetylhydrolase assay kit (product number 760901, Cayman Chemicals), according to the manufacturer's instructions, by using 2-thio PAF as a substrate and 5,5Ј-dithiobis-(2nitrobenzoic acid) (DTNB; Ellman reagent) as the detecting reagent.
Immunoblotting, indirect immunofluorescent staining, immunohistochemical staining, real-time RT-PCR, flow cytometry assay, lucigenin-enhanced chemiluminescence assay, transient transfection and luciferase assay, and small interfering RNA (siRNA) experiments were performed as previously described. [1] [2] [3] [4] [5] [6] [7] 
Statistical Analysis
Data expressed as meanϮSEM were analyzed with a 2-tailed Student t test for 2 groups or 1-way ANOVA for different groups. A value of PϽ0.05 was considered statistically significant.
Detailed materials and methods are given in the online-only Data Supplement.
Results
Pla2g7 Is Upregulated During SMC Differentiation
To fully understand the molecular mechanisms underlying SMC differentiation, microarray analysis was conducted with total mRNA isolated from differentiating SMCs. We observed that Pla2g7 gene expression was significantly increased on SMC differentiation. To further confirm this finding, ES cells were seeded on mouse collagen IV-coated flasks and cultured in the absence of leukemia inhibitory factor for 4 to 14 days to allow SMC differentiation as described previously. [1] [2] [3] [4] [5] [6] [7] As shown in Figure 1A , gene expression levels of SMC differentiation-specific marker were significantly induced in our stem cell differentiation model. Importantly, stem cell-specific transcription factors of octamer-binding transcription factor 4 and Nanog were significantly downregulated after withdraw of leukemia inhibitory factor and on SMC differentiation ( Figure 1B ). Taken together, these data strongly suggest that collagen IV can drive ES cell differentiation toward SMCs with induction of SMC differentiation genes and inactivation of stem cell specific transcription factor gene expression. Interestingly, the gene expression levels of Pla2g7 were significantly induced in our SMC differentiation model, peaked at day 8, and displayed a sustained signal until day 14 ( Figure 1C ). Because no commercial antibody for detecting Pla2g7 protein level with Western blot analysis is currently available, we alternatively measured the enzymatic activity of Pla2g7 to represent Pla2g7 protein activity. Similar to its gene expression, Pla2g7 activity displayed a significant induction during SMC differentiation process ( Figure 1D ). To detect the expression pattern of Pla2g7 in the ES cells and differentiating cells, double immunofluorescence staining with antibodies against Pla2g7 and the smooth muscle-specific markers (SM␣A, SM22␣, and calponin) was performed on undifferentiated ES cells or day 8 differentiated SMCs that coincided with the peak of Pla2g7 expression. As expected, Pla2g7 expression was absent in undifferentiated ES cells, but its expression, displaying a patch and particle pattern resembling the typical expression of secreted enzymes, was colocalized with the smooth muscle markers ( Figure 1E ). Notably, some transforming SMCs also expressed comparable level of Pla2g7 ( Figure 1E , white arrows). Moreover, flow cytometry analysis showed that 47.5Ϯ1.8%, 51.8Ϯ3.7%, and 75.8Ϯ1.16% of cells in the day 8 of cell culture were positive for Pla2g7, smooth muscle-myosin heavy chain (SM-MHC), and SM␣A, respectively ( Figure 1F ). These data strongly suggest that ES cells can be efficiently induced to differentiate toward SMCs and that Pla2g7 may play a role in this process.
Pla2g7 Plays an Important Role in SMC Differentiation In Vitro
To investigate whether Pla2g7 expression plays any role in SMC differentiation from stem cells, Pla2g7 expression plasmids were successfully generated, and overexpression experiments were conducted in differentiating ES cells. The experiments showed that enforced Pla2g7 expression increased Pla2g7 protein activity ( Figure 2A ) and, more importantly, induced the expression of SMC-specific genes (SM␣A, SM22␣, calponin, and SM-MHC) ( Figure 2B and 2C), suggesting that Pla2g7 overexpression can promote collagen IV-initiated SMC differentiation from ES cells. To quantify the effects of Pla2g7 overexpression on SMC differentiation more accurately, flow cytometry analysis was conducted to detect calponin expression in the cells overexpressing Pla2g7. As shown in Figure 2D , enforced Pla2g7 expression in the differentiating cells induced more SMC differentiation from stem cells (70.69Ϯ5.98% versus 31.44Ϯ4.6%). To further test whether Pla2g7 was essential for SMC differentiation, siRNA knockdown experiments were performed in differentiating ES cells using Pla2g7 or control siRNA. The experiments revealed that knockdown of Pla2g7 inhibited expression of smooth muscle differentiation specific markers (SM␣A, SM22␣, h1-calponin, SM-Myh11) at both RNA ( Figure 2E ) and protein ( Figure 2G ) levels, as well as Pla2g7 protein activity ( Figure 2F ), suggesting that Pla2g7 expression is necessary for SMC differentiation from stem cells. To investigate whether overexpression of Pla2g7 can rescue Pla2g7 siRNA-mediated SMC differentiation impairment, day 5 differentiating ES cells were cotransfected with control (pCMV5) or Pla2g7 expression plasmids pCMV5-Pla2g7 (3 g/10 6 cells) and control random siRNA or Pla2g7 siRNAs (100 nmol/L). Data shown in Figure 2H further confirmed that knockdown of Pla2g7 significantly downregulated SMC specific genes, such as SMaA and SM-MHC, whereas overexpression of pla2g7 dramatically upregulated SMC genes. Interestingly, our data also showed that the gene expression levels of SMC markers in cells cotransfected with Pla2g7 A, Induction of SMC differentiation markers during stem cell differentiation. Undifferentiated embryonic stem (ES) cells were plated in dishes coated with 5 g/mL of collagen IV and cultured in the differentiation medium. Total RNA from undifferentiated ES cells (d0) or differentiating ES cells at days 4 (d4), 8 (d8), 10 (d10), 12 (d12), and 14 (d14) were harvested and subjected to real-time polymerase chain reaction (PCR) analysis with specific primer pairs for SM␣A and smooth muscle-myosin heavy chain (SM-MHC). B, Stem cellspecific transcription factors were rapidly silenced during SMC differentiation. The same RNA samples were used to measure the gene expression levels of octamer-binding transcription factor 4 (Oct4) and Nanog. C and D, Pla2g7 gene expression and protein activity were significantly increased during stem cell differentiation. Total RNA and cell lysate from undifferentiated ES cells (d0) or differentiating ES cells were harvested and subjected to real-time PCR analysis with specific primer pairs for Pla2g7 (C) and Pla2g7 protein activity analysis with the platelet-activating factor acetylhydrolase (PAF-AH) activity assay kit (D). E, Pla2g7 protein level was undetectable in undifferentiated ES cells but significantly upregulated during SMC differentiation and colocalized with SMC-specific markers in differentiated SMCs. Double immunofluorescence staining was conducted on undifferentiated ES cells and day 8 differentiated SMCs with antibodies against Pla2g7 and SMC-specific markers (SM␣A, SM22␣, and calponin). White arrows indicate transforming SMCs that expressed comparable level of Pla2g7 and low levels of SMC markers. F, Flow cytometry analysis. Day 8 differentiating cells were harvested and subjected to flow cytometry analysis with Pla2g7, SM-MHC, and SM␣A-specific antibodies, respectively. Representative flow cytometry analysis images and the percentage of positive cells in the day 8 differentiated cells are presented here. The data presented here are representative or meanϮSEM of 3 independent experiments. Significant difference from control, *PϽ0.05. siRNAs and expression plasmid were significantly higher than those in cells transfected with Pla2g7 siRNA alone and despite SMC gene expression levels in cells cotransfected with Pla2g7 siRNAs and expression plasmid were slightly lower, but comparable to that in cells transfected with Pla2g7 expression plasmids alone, indicating Pla2g7 overexpression can rescue Pla2g7 siRNA-mediated SMC differentiation impairment. To further test whether Pla2g7 expression is specific for SMC differentiation in our system, Pla2g7 gene overexpression experiments in differentiating ES cells were performed. The chosen cell lineage markers based on our previous findings as they displayed upregulation during ES cell differentiation on collagen IV 3 were analyzed with real-time RT-PCR. Apart from SMC differentiation genes, none of the markers for other cell lineages tested, with the exception of 1 cardiac-specific gene actc-1 (␣-actin, cardiac muscle-1), was found to be induced by Pla2g7 gene expression ( Figure I in the online-only Data Supplement), indicating that Pla2g7 plays a role, likely specifically, in SMC differentiation.
To further validate the role of Pla2g7 in SMC differentiation from adult progenitor cells, stem cell antigen 1-positive (Sca-1 ϩ ) cells isolated from vessel adventitia as described previously 10 were transfected with different amount of control (pCMV5) or Pla2g7 expression plasmids pCMV5-Pla2g7 and initiated to SMC differentiation. As shown in Figure II in the online-only Data Supplement, overexpression of Pla2g7 in Sca-1 ϩ cells significantly upregulated SMC gene expression, indicating that Pla2g7 also plays a role in SMC differentiation from adult progenitors.
Pla2g7 Also Plays a Role in SMC Differentiation In Vivo
To investigate the involvement of Pla2g7 during cardiovascular development, single (Pla2g7 alone) or double (Pla2g7 and SM␣A or SM-MHC) immunohistochemical stainings were performed in cross-sections of mouse embryos (days 9.5 and 12.5), heart, aorta, lung, kidney, and skeletal muscle. Pla2g7 was strongly expressed in some cell clusters that were negative for the SMC marker SM␣A in the day 9.5 mouse embryos ( Figure IIIA and IIIA1 in the online-only Data Supplement). Interestingly, we observed that Pla2g7 expression was more profound in cells transforming/differentiating into SM-MHC-positive cells (cells double positive for Pla2g7 and SM-MHC; indicated by black arrows in Figure IIIB1 Figure IIIJ in the online-only Data Supplement). The expression patterns of Pla2g7 in mouse embryos and adult heart, aorta, skeletal muscles, lung, and kidney tissues strongly suggest that Pla2g7 might play a role in cardiovascular development in vivo. To further explore the functional role of Pla2g7 in SMC differentiation in vivo, Pla2g7 knockdown and control ES cell lines were generated by using Pla2g7 and nontarget shRNAs, respectively. Similar to its parent ES cells, Pla2g7 was undetectable in Pla2g7 knockdown and nontarget control ES cells ( Figure 3A) . During SMC differentiation, however, Pla2g7 gene expression levels were significantly increased in nontarget shRNA-infected cells but only slightly increased in Pla2g7 shRNA-infected cells (Figure 3A ), suggesting that Pla2g7 gene expressions were successful knockdown in these cells. Platelet-derived growth factor-BB was reported extensively as a powerful SMC differentiation inducer in vitro. 1,4 -5,10 To investigate whether Pla2g7 knockdown impairs in vivo SMC differentiation potential, nontarget and Pla2g7 shRNA-infected ES cells were subcutaneously coinjected into C57BL/6J mice with 100 ng/mL platelet-derived growth factor-BB to promote in vivo SMC differentiation. Hematoxylin/eosin staining showed that muscle tissues/structures formed in the implants of nontarget shRNA-infected ES cells, but fewer tissues/ structures were observed in the implants of Pla2g7 shRNAinfected ES cells ( Figure 3B ). Consistently, immunofluorescence staining with antibodies against SM␣A and SM-MHC showed that a large number of SM␣A-or SM-MHC-positive cells were present in the implants of nontarget shRNAinfected ES cells, whereas many fewer SM␣A-or SM-MHCpositive cells were observed in the implants of Pla2g7 shRNA-infected ES cells ( Figure 3C and 3D ). As expected, the majority of cells in the Matrigel implants were ␤-galactosidase positive, indicating its exogenous origins ( Figure 3C ). Importantly, real-time PCR analysis showed that Pla2g7 gene expression levels in the Matrigel implants of Pla2g7 shRNA-infected ES cells were significantly lower than those of nontarget shRNA-infected ES cells ( Figure 3E) , further confirming the efficiency of Pla2g7 knockdown and the importance of Pla2g7 in SMC differentiation. Taken together, these data clearly suggest that Pla2g7 plays an important role in SMC differentiation from stem cells in vitro and in vivo.
We further wondered whether knockdown of Pla2g7 in stem cells affects its ability to differentiate into other cell lineages, such as endothelial cell, macrophage, osteoblast, and adipocyte, in our system. Sections prepared from the above implants were subjected to immunofluorescence staining with antibodies against CD144, CD68, FABP4, and osteoadherin to detect endothelial cells, macrophages, adipocytes, and osteoblasts, respectively. Data shown in Figure  IV in the online-only Data Supplement revealed that although the numbers of CD68-positive macrophage and FABP4positive adipocytes were significant lower in the implants of Pla2g7 shRNA-infected ES cells than in the implants of nontarget shRNA-infected ES cells, no significant difference was observed in terms of CD144-positive endothelial cells and osteoadherin-positive osteoblasts numbers between the 2 groups, indicating possible involvements of Pla2g7 in macrophage and adipocyte specification from stem cells.
Superoxide, but Not Hydrogen Peroxide, Mediates Pla2g7-Induced SMC Differentiation
The amount of ROS generated and their balance is essential for SMC differentiation from stem cells, as demonstrated in our previous studies, [2] [3] 25 and as mentioned earlier, Pla2g7 is supposedly involved in ROS balancing by generating or inactivating oxidative products. To clarify whether Pla2g7 was involved in such a process in our SMC differentiation model, differentiating ES cells were transfected at day 4 with increasing doses of the pCMV5-Pla2g7 (1, 3, 6 g/10 6 ) or with empty pCMV5 vector as a control. Forty-eight hours after transfection, NADPH oxidase (Nox) activity and superoxide formation were assessed using the lucigenin-enhanced chemiluminescence assay. The experiments showed that NADPH-derived superoxide production was significantly increased by overexpression of Pla2g7 ( Figure 4A ). Notably, ROS generation peaked at middle dose of Pla2g7 expression plasmids and was slightly brought back by highest dose of Pla2g7 expression plasmids, suggesting that some antioxidant signaling was activated by excess amount of Pla2g7 or ROS. To identify the superoxide source, various inhibitors of superoxide producing enzymes were applied. As shown in Figure 4B , superoxide production was attenuated by flavoprotein-specific inhibitor DPI and the superoxide scavenger Tiron but was not significantly affected by other inhibitors, such as mitochondrial respiratory chain complex I (Rotenone), II (thenoyltrifluoroacetone), xanthine oxidase inhibitor (allopurinol), or nitric oxide synthase (NOS) inhibitor (L-NAME), which suggests that Noxs are involved in ROS generation during SMC differentiation as well as Pla2g7-mediated ROS production. Because the most common ROS are superoxide (O 2 ⅐ Ϫ and OH ⅐ ) and hydrogen peroxide (H 2 O 2 ), we further tested which type of ROS generation induced by Pla2g7 is involved in Pla2g7 expressionmediated SMC differentiation. As shown in Figure 4C to 4E, Pla2g7-induced SMC differentiation gene expression were significantly abolished by free radical scavenger N-(2-mercapto-propionyl)-glycine ( Figure 4C ) and flavoprotein inhibitor of NADPH oxidase-DPI ( Figure 4D ) but not hydrogen peroxide inhibitor-catalase ( Figure 4E ), suggesting that superoxide, but not hydrogen peroxide, is involved in Pla2g7 mediated SMC differentiation.
Pla2g7 Mediates SMC Differentiation Through Modulation of SRF Binding to SMC-Specific Gene Promoter by Increasing SRF Phosphorylation Levels
The transcription factor SRF and its cofactor myocardin play crucial roles in SMC differentiation and embryonic cardiovascular system development. 26 -33 Importantly, both SRF and myocardin, like Pla2g7, are significantly upregulated in our SMC differentiation system. 3 Therefore, we decided to investigate whether these factors worked in concert. Unexpectedly, overexpression of Pla2g7 seemed to have no significant effect on SRF and myocardin gene/protein expression ( Figure 5A and B), suggesting that the SRF and myocardin gene expression is not regulated by Pla2g7. Because SRF and myocardin regulate SMC differentiation gene expression through the binding of SRF/myocardin complex to CArG boxes in SMCspecific gene promoters, thus activating SMC-specific gene transcription and expression, we wondered whether Pla2g7 mediates SMC differentiation through modulating the binding capacity of SRF/myocardin complex to SMC-specific gene promoters. To test whether Pla2g7 overexpression affected the recruitment of SRF/myocardin complex to SMC gene promoter regions, ChIP assays were performed with SRF-specific antibodies and primers specific for SM␣A and SM22␣ gene promoters containing CArG box. The experiments showed that Pla2g7 overexpression significantly increased SRF binding to the SM␣A ( Figure 5C ) and SM22␣ promoters ( Figure 5D ). Strikingly, the induction of SRF binding to SM␣A and SM22␣ gene promoters was abolished by N-(2-mercapto-propionyl)-glycine and DPI, but not by catalase, indicating that Pla2g7 modulates SRF/myocardin complex binding to SMC-specific gene promoters through generation of superoxide, but not hydrogen peroxide. This is consistent with and further confirmed the above finding that Pla2g7 regulates SMC differentiation through superoxide, but not hydrogen peroxide. Previous evidence suggests that SRF can be phosphorylated by casein kinase and mitogen-activated protein kinase activated by growth factors or ROS, which increases its DNAbinding activity/affinity, its interaction with cofactors, or both. 3,34 -37 Therefore, we further investigated whether Pla2g7 overexpression increases SRF phosphorylation levels. Indeed, data shown in Figure 5E revealed that the phosphorylation level of SRF was significantly increased in the cell overexpressing Pla2g7, but its induction was almost abolished in the presence of N-(2-mercapto-propionyl)-glycine and DPI. The above data strongly suggest that Pla2g7 mediates the increase of binding of SRF to SMC-specific gene promoters through modulation of SRF phosphorylation by superoxide generation.
Nrf3 Is an Upstream Regulator of Pla2g7
Our previous study demonstrated that nuclear factor erythroid 2-related factor 3 (Nrf3), a member of the cap 'n' collar family of transcription factors, plays a crucial role in ROS balance and SMC differentiation from stem cells. 2 To investigate the mechanism of Pla2g7 regulation, knockdown experiments were conducted with specific Pla2g7 siRNA and Nrf3 siRNA in differentiating cells. The gene/protein expression levels of both genes and Pla2g7 protein activity were analyzed by real-time RT-PCR ( Figure VA These data strongly suggest that Nrf3 is an upstream regulator of Pla2g7 gene regulation.
Nrf3 Regulates Pla2g7 Gene Expression Through Transcriptional Activation
To further clarify how Nrf3 regulates Pla2g7 gene expression, differentiating ES cells were transfected with pef-BOS-Nrf3 or pef-BOS, treated with actinomycin D (1 g/mL for 6 hours) or vehicle, and analyzed by real time RT-PCR. Actinomycin D ablated the effect of Nrf3 overexpression on the gene expression levels of Pla2g7 ( Figure 6A ). To further elucidate the possibility that Nrf3 regulates Pla2g7 at the transcriptional level, we first attempted, but failed, to generate a long promoter of Pla2g7 gene (up to 3 kb from translation start site). Alternatively, we designed a set of specific primers (10 pairs) spanning an Ϸ3 kb upstream region of Pla2g7 gene as illustrated in Figure 6B and performed a ChIP assay with Nrf3 antibody to test whether Nrf3 can directly bind to Pla2g7 gene promoter or whether such binding is regulated by Nrf3 expression level. Data shown in Figure 6C revealed that Nrf3 directly binds to 2 regions of the Pla2g7 gene promoter (1 around Ϫ2.4 kb upstream of and the other close to the translation start site) and that Nrf3 overexpression significantly increased its binding to both of these regions of the Pla2g7 gene promoter. Importantly, we successful generated 4 shorter Pla2g7 gene promoter reporters containing DNA sequence of different regions of the Pla2g7 promoter ( Figure 6B , reporter contains the region between F1 and R1 are referred to as Pla2g7 reporter 1, or pGL3-mPla2g7-P1, and so on) and performed a luciferase gene reporter assay. Our data revealed that Nrf3 overexpression significantly increased the activity of Pla2g7 reporters 2 and 9 but had no effect on Pla2g7 reporter 1 or 10 ( Figure 6D) , which is consistent with and further supports our findings from the ChIP assay. These data indicate that Nrf3 directly activates the Pla2g7 gene at transcriptional level. Figure 5 . Phospholipase A 2 , group 7 (Pla2g7) modulates serum response factor (SRF) binding to smooth muscle cell (SMC)-specific gene promoter. A and B, SRF and myocardin gene expression levels were not affected by Pla2g7. Differentiating embryonic stem (ES) cells were transfected at day 4 with pCMV5-Pla2g7 or pCMV5 (3 g/10 6 cells) and cultured for a further 2 to 3 days in differentiation medium. Total RNA and protein were harvested and subjected to quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) (A) and Western blot analysis (B) analysis, respectively. ␣-Tubulin was included as internal control. C and D, N-(2-Mercaptopropionyl)-glycine (NMPG) and diphenylene iodonium (DPI), but not catalase, abrogated the induction of SRF binding to SMC-specific gene promoter induced by Pla2g7. Differentiating ES cells were transfected at day 4 with pCMV5-Pla2g7 or pCMV5 (3 g/10 6 cells) and cultured for a further 48 to 56 hours, followed by incubation with NMPG, DPI, and catalase or dimethyl sulfoxide (DMSO) (which served as vehicle) overnight before sample harvest. Chromatin immunoprecipitation assays were performed using antibody against SRF. Rabbit IgG was used as a negative control. Aliquots of chromatin before immunoprecipitation served as an input control. Precipitated chromatin DNA was used to amplify the promoter regions of SM␣A (C) and SM22␣ (D) genes by PCR with specific primers. The immunoprecipitation efficiency with SRF antibody was 12.5Ϯ3.6%. The data presented here are representative (upper panels) or meanϮSEM of 3 independent experiments (lower panels). *PϽ0.05 (pCMV5-Pla2g7 vs pCMV5), #PϽ0.05 (NMPG or DPI vs DMSO). E, Overexpression of Pla2g7 increase SRF phosphorylation level. Differentiating ES cells were transfected at day 4 with pCMV5-Pla2g7 or pCMV5 (3 g/10 6 cells) and cultured for a further 48 to 56 hours, followed by incubation with NMPG, DPI, and catalase or DMSO (which served as vehicle) overnight before sample harvest. Cell lysates were harvested and subjected to standard Western blot analysis. Numbers under the bands indicate the average relative expression levels of target proteins from 3 independent experiments. 
Discussion
In the present study, we have uncovered a previously unrecognized function of Pla2g7, a circulating enzyme that is traditionally recognized as an important mediator in lipid metabolism and oxidization, that Pla2g7 also plays an important role in stem cell differentiation toward SMCs in vitro and in vivo. We also demonstrate that Pla2g7 is involved in ROS generation and balance during SMC differentiation from stem cells and that it regulates SMC differentiation gene expression through modulation of SRF/myocardin complex binding to SMC-specific gene promoters, which is induced by superoxide but not by hydrogen peroxide. We further demonstrate that Nrf3 regulates Pla2g7 gene expression and protein activity through direct binding to Pla2g7 gene promoter. Based on the evidence provided in the present study and previous studies from our group and others, we propose that fine regulation of Nrf3-Pla2g7-superoxide-SRF/myocardin-SMC-specific gene interactions is critical for SMC differentiation from stem cells ( Figure VI) . In this signaling pathway, Nrf3 are activated by endoplasmic reticulum stress. After activation, Nrf3 regulates Pla2g7 gene expression and protein activity through transcriptional activation. Upregulated Pla2g7 promotes superoxide generation that modulates the binding of SRF to SMC differentiation gene promoters, resulting in SMC differentiation gene expression.
Pla2g7 Expression in Cardiovascular Tissues and Indications
It was believed that Pla2g7 is mainly produced and secreted into the plasma by hematopoietic stem cell-derived cells, such as monocyte/macrophages, 38 -39 mast cells, 40 T-lymphocytes, 39 platelets, [41] [42] and tissue sources that are consistent with the macrophage origin of the enzyme. 43 Accordingly, the physiological and pathological functions of Pla2g7 have been proposed to be the major mediator of the inflammatory process because of its inflammatory cellular source. Later studies also suggested that Pla2g7 is an expressional candidate for early and intermediate disease progression and that its expression in the diseased aortas is significantly increased. 44 Consistently, an increase in pla2g7 expression has also been identified in macrophages of both human and rabbit atherosclerotic lesions 39 and in an atherosclerosis-prone mouse model. 45 Initially, it was believed that macrophage and lymphocytes are major cellular source in the atherosclerotic lesions, and its expression level in SMCs was undetectable 39 ; however, a recent study has revealed that a strong signal and high expression level of Pla2g7 are also detected in SMCs. 46 Importantly, the authors observed strong expression of Pla2g7 in the SMCs localized in the media of human atherogenic aorta and nonatherogenic mammary artery aortas, 46 implying that Pla2g7 may play an additional role in the vessel wall. In the present study, we further confirmed its expression in the ES-derived SMCs (Figure 1E ), embryonic SMCs ( Figure IIIB in the online-only Data Supplement), and vascular SMCs ( Figure IIIF , IIIH, IIII, and IIIJ in the online-only Data Supplement) and identified a novel role of Pla2g7: we found, for the first time, that Pla2g7 expression is crucial for SMC differentiation from stem cells. Importantly, we observed strong positive staining signal for Pla2g7 in differentiating/transforming SMCs during the ES cell differentiation process (cells indicated by white arrows in Figure  1E displayed a weak SMC marker expression and strong Pla2g7 expression pattern), as well as embryonic smooth muscle development (black arrows in Figure IIIB1 in the online-only Data Supplement), suggesting that Pla2g7 may play a causal role in SMC differentiation. Recent studies have revealed that there are various vessel residential stem/progenitor cells in the vessel wall 10, [47] [48] [49] and that such stem/ progenitor cells can differentiate into SMCs and participate in atherosclerotic/neointimal lesion formation. 10 -12 Based on the evidence provided in the present study and the findings observed by other researchers, 46 we propose that, besides its pro-or antiatherogenic role in atherosclerosis development and cardiovascular disease progression, Pla2g7 may have a novel role in maintaining intact vascular structures or exerting its physiological functions of the arterial wall by modulating vascular SMC differentiation from residential stem/ progenitor cells.
Molecular Mechanisms of Pla2g7-Mediated SMC Differentiation: Superoxide Generation
We observed that Pla2g7 overexpression enhanced the NADPH-derived ROS production during SMC differentiation and demonstrated that superoxide, but not hydrogen peroxide, is responsible for Pla2g7 mediated SMC-specific gene expression, which suggests that ROS generation is 1 of the possible downstream effectors of Pla2g7 gene activation to mediate SMC differentiation from stem cells. ROS is highly reactive and important in cellular signaling pathways involved in vascular physiology and pathogenesis (hypertension, atherosclerosis, and restenosis). 50 The most common ROS in cardiovascular system include superoxide (O 2 . ), hydrogen peroxide (H 2 O 2 ), and peroxynitrite (ONOO -). Previous studies have demonstrated that ROS generation and balance play a crucial role in vascular SMC proliferation, migration, and differentiation under different circumstances. 51, 52 For SMC differentiation, ROS have been suggested to enhance SMC differentiation through a ROS/p38 mitogen-activated protein kinase-dependent increase in SRFmediated transcriptional activation. 52 We and others further identified that the main enzymatic source of ROS mediated SMC differentiation and required for maintenance of the differentiated vascular SMC phenotype is Nox4. 3, 53, 54 Mechanistically, our previous study also suggests that Nox4 mediates SMC differentiation through activation of SRF and myocardin. 3 It was believed that the SRF-CArG interaction is a critical convergence point for signals that either activate SMC gene expression to promote SMC differentiation under physiological environments or repress SMC gene expression during pathophysiological conditions, and SRF-CArG box interactions confer context-dependent and signal-responsive control of muscle-specific gene transcription, which is accomplished at multiple levels of regulation, including control of SRF expression, cytoplasmic to nuclear translocation, alternative splicing, and posttranslational modifications of SRF itself. 55 In this study, we observed that Pla2g7 activation or its generated superoxide has no significant effect on SRF and myocardin gene activation but can dramatically increase SRF binding to SM␣A and SM22␣ gene promoter through increasing phosphorylation of SRF by superoxide generation. Taken together, our data suggest that Pla2g7 mediates SMC differentiation from stem cells through phosphorylation of SRF by generating superoxide, which in turn increase the binding of SRF to SMC-specific gene promoters. Epigenetic control mechanisms-particularly histone modification, which is tightly controlled by histone acetyl transferases and histone deacetylases (HDACs), as well as histone methyltransferases and demethylases-are believed to play a key role in regulating the differentiation of cardiovascular cells, including SMCs, endothelial cells, and cardiac muscle cells (reviewed by Ohtani and Dimmeler 56 ). For SMC differentiation, our study and others provide strong evidence that HDACs, particularly HDAC3 57 and HDAC7, 1,4 play important role in SMC differentiation. Therefore, it might be a plausible question to ask whether Pla2g7-generated ROS affect histone modification and whether histone modification enzymes such as HDAC and histone methyltransferase play a role in Pla2g7-mediated SMC differentiation. To seek this answer, differentiating ES cells were transfected at day 4 with pCMV5-Pla2g7 or pCMV5 (3 g/10 6 cells), followed by incubation with trichostatin A (HDAC inhibitor), BIX01294 (histone methyltransferase inhibitor), or dimethyl sulfoxide (which served as vehicle) for 48 hours. Our unpublished data show that neither trichostatin A nor BIX01294 plays a significantly role in Pla2g7-mediated SMC gene regulation, indicating that Pla2g7 mediates SMC differentiation maybe independent of histone modification. Additionally, our data also revealed that Pla2g7 overexpression has no effect on HDAC3 and HDAC7 gene activation (data not shown), further suggesting that Pla2g7, HDAC3, and HDAC7 seem to play an independent role in regulating SMC differentiation.
Pla2g7 Gene Regulation and Cellular Differentiation
Cellular differentiation is a critical process in normal embryonic development and organogenesis and is an important determinant in diseases such as neointimal lesion formation and cancer progression. Apart from its crucial role in SMC differentiation, Pla2g7 seems also involve in macrophage and adipocyte cell lineage specification, which is consistent with previous findings that Pla2g7 involves in macrophage and megakaryocyte differentiation through modulating the PAF signal system. 58, 59 It is believed that Pla2g7 gene expression and secretion are regulated by several exogenous stimuli, such as PAF, lipopolysaccharides, and a variety of cytokines and steroid hormones, 19 through transcriptional mechanisms that are dependent on the state of cellular differentiation. 60 Moreover, it has been reported that the Pla2g7 promoter contains a set of GC-rich motifs surrounding the transcription start site and multiple regions harboring responsive elements for cellular differentiation-related transcription factors, such as signal transducer and activators of transcription-related proteins and myeloid-specific transcription factors. 61, 62 Furthermore, the binding of the transcription factors Sp1 and Sp3 to both canonical and noncanonical Sp-binding sites localized within the minimal promoter region participates in the constitutive expression of human plasma Pla2g7 gene in macro-phages, 62 and is required for lipopolysaccharide-induced Pla2g7 gene transcriptional activation. 63 Interestingly, our recent study demonstrated that the levels of Sp1 are high in differentiating stem cells and that Sp1-dependent HDAC7 activation is required for SMC differentiation from stem cells, 1 which may explain the elevated expression of Pla2g7 associated with differentiation of stem cells into SMCs. In the present study, we provide strong evidence that Pla2g7 gene expression is transcriptionally regulated by transcription factor Nrf3, 1 of the important determinants for SMC differentiation from stem cells as demonstrated in our previous study. 2 Our ChIP assay also revealed that Nrf3 directly binds to 2 regions (1 around Ϫ2.4 kb upstream of and the other close to the translation start site) of the Pla2g7 gene promoter ( Figure 6C and 6D) . It is reported that Nrf3 binds to ARE. 64 However, there is no consensus AU-rich element binding site present in the Pla2g7 gene promoter region, suggesting that Nrf3 may also bind to one or more other elements yet to be identified. The ChIP assay showed that Nrf3 binds to the same region of DNA as SRF, Sp1, cAMP-response element binding protein, and signal transducers and activators, though we cannot conclude whether it is the same site. To define the exact binding site, additional in vitro binding assays, deletion constructs and direct sites mutational analysis of the Pla2g7 gene promoter will be required.
In summary, Pla2g7 gene expression and protein activity are significantly upregulated during stem cell differentiation into SMCs, and its expression in differentiated SMCs has also been demonstrated in the present study. Our data from gene gain and loss experiments in the differentiating ES cells further confirmed that Pla2g7 is essential for SMC differentiation from ES cells. Importantly, we also provide a novel mechanism for Pla2g7 gene transcriptional regulation by Nrf3. Taken together, we have identified a SMC differentiation regulation signaling pathway that involves fine regulation of Nrf3-Pla2g7 and ROS generation and shown the importance of Pla2g7 for SMC differentiation from stem cells, which may contribute to the understanding of cardiovascular development and its physiological importance in normal cardiovascular biology or pathological roles in cardiovascular diseases.
